Ayala Pharmaceuticals Inc (EM) (ADXS)

I got .72 per shrs. and now saying spin-off. hmmm

Anyone. Just checked my old account and saw some shares of ADXS. Do they still have some value to it? Is there a way to get some $ from these shares? TIA.

ADXS: Company Dissolved. Transfer Books Closed

FINRA deleted symbol

https://otce.finra.org/otce/dailyList?viewType=Deletions

Form 15, to de-register.

Sorry I keep putting IMNU I mean IMNM

Well IMNU holding just hit $60 million or there abouts.

Actually make that $50 million at todays IMNU price

Agree they hold over well $40 million in IMNU stock

Under 70 cent is a bargain.

Aye aye. Good luck with it.

Looking at filing I think the deal will close very quickly as most of the shares are held by a few investors or funds, I see Feb 8th mentioned in the filing for funds to approve.

Well the market obviously likes the deal.

I wish it was mine but talking about the increase ADXS has seen in its holding of IMNU stock, when deal goes through.

Nice work, James.

Well IMNU just hit $25, so that $30 million just became $54 million on paper in stock.

Only 3 milly floater too. :)

What price did u bought them at?

I just noticed the actual amount of shares ADXS will get, it’s 2,175,489 shares which at $22 a share which is IMNU current share price that is $48 million.

ADXS got the shares at $13.79 in this deal disclosed today.

Add the $20 million in cash and $37 million in milestones.

ADXS current market cap is just under $15 million.

For the first time in a longtime I can say ADXS is cheap, very cheap.

Well snagged a few thousand at open, no brainer with news this morning.

Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile


BOTHELL, Wash. and MONMOUTH JUNCTION, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, to acquire AL102 and related drug candidate AL101 from Ayala. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing and will pay up to an additional $37.5 million in development and commercial milestone payments. Completion of the transaction is subject to customary conditions including Ayala obtaining the requisite stockholder approval.

$ADXS - Ayala Pharmaceuticals to Merge w/ Biosight Ltd, a privately-held pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders
To close prior to Q3 23
Float under 5 m

$ADXS - Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Merger to add a clinical stage oncology asset to Ayala’s portfolio with data anticipated in the H1 '24

$ADXS - Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Merger to add a clinical stage oncology asset to Ayala’s portfolio with data anticipated in the H1 '24

Hi GF
Check Qbts And Rxrx could move soon

Hi GF
Into Qbts and some bzfd with a sprinkle of Rxrx could be riding a wave 🍾🍾👍👍

Advaxis Inc. changed to Ayala Pharmaceuticals Inc.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

ASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2 mg once daily (the selected Phase 3 dose)

Tumor response, volume and T2 signal reduction were observed earlier in the 1.2 mg once daily group, with deeper and sustained treatment responses

Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally.

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced updated results from Phase 2 (Part A segment) of the RINGSIDE study evaluating AL102 in desmoid tumors. The results are summarized in an abstract published today for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. More detailed results will be featured in a poster session at ASCO on Saturday, June 3. AL102 is a once-daily, potent, selective, oral gamma-secretase inhibitor (GSI).

The only safe haven for $$$$ these days seems to be under the mattress.

What a turd. CEO Ken is running this into the ground with his carelessness.

$ADXS

Another massive bank shockingly failed. One day it's biz as usual, the next day, total implosion. Banking customers freaking the fvck out.

Omg. Geez. I know how that feels...like right after that first massive R/S. At that point, subsequent R/S further obliterated what little was left.

Expensive lesson of the game for sure. All the wiser.

The banking news this week makes the losses suffered over the many years in this next of the woods look like shriveled mouse nuts.

Just think, in just another 7 years, and who knows how many more R/S between now and then, this biz will have somehow survived, what???

Will it be THREE DECADES???

OMG.

Enuff said....

If there is any justice in this universe, both Ken the sleasebag lawyer and Sidransky the supposed doctor with no patients and primary allegiance to his Israeli hedge fund companies, will spend the next decade or so in prison to account for their sins.

Looks like things are picking up we may surpass 1000 bucks in total trades today

Well it’s certainly been a learning experience. I would not say broke as I sold enough on the run to $30 to cover my initial investment and some. I left a lot on the table and could have been set up nicely if I had sold all.

I have made some up on other stocks and one thing I learned was to spread the money around and not be over invested in 1 stock.

James, Are you as broke as I am from ADXS?

Hmm (Glancing at the EOY PPS).

Some things never change.

Them pesty R/S's pop up quicker than weeds at springtime in these parts.

Waiting patiently for the next 20 for 1 reverse split.......

Crickets.

I see alot of same names (fellow bag holders) still posting here… anyone recovered their ADXS losses from elsewhere yet?

The last of someones FTX crypto currency investdonation......?

Salmon man adding?

That was blue eyes, she is still buying

Volume posted this early AM:

"1"


Totally laughable.

Not sure what data you are referring to. Is it this:"ADXS-503: Phase 1/2 combination with KEYTRUDA updated clinical and immune/biomarker data for KEYTRUDA failures and initial readout in first-line patients"? Haven't been following this POS for some time...

Hi Nick,

So my Ph.D. is in plant biology (breeding and natural products), but I actually worked in a medicinal chemistry lab modifying natural products for improved pharmacological function. I own multiple patents on plants that have improved phenotypic characteristics.

I bring this up, because I know a lot about fungi and psilocybin. Personally, I think Lions Mane is the most valuable fungi due to its neuroregenerative properties. However, psilocybin seems to be incredibly promising in addiction and end of life care. I haven't looked at the landscape, but I know Peter Thiel backed this pharma company.

https://atai.life/

They are on a huge hiring spree at the moment for senior level members.

https://boards.greenhouse.io/atai

I'm hearing a lot of chatter about psylocybin mushrooms being used for medicinal purposes. Don't know if that fits into your area of expertise or not.....just throwing it out there

Thanks man, much appreciated. Good luck and stay safe.

Don’t give up, Phyto. Network, and talk to as many people as possible. You never know where an idea may come from. All of my best to you.

Thanks and ya, it has been difficult but thanks for your thoughts. I have been looking at head hunters but they have told me multiple times that they do not utilize scientists in the way I want to work lol. But I will keep trying.

Good news on AVXL, thanks for the heads up years ago!